Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

NCT05731947 ↗

Phase 1/2 Terminated 41 enrolled Syndax Pharmaceuticals

Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.

Timeline

Start: 2023-04-04
Primary completion: 2025-06-30
Completion: 2025-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Regorafenib	Small molecule	—	—
Subject	Revumenib	Small molecule	—	Oral
Subject	TAS-102	Small molecule	—	—

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Summary

Timeline

Drugs

Indications